Innate Pharma highlights abstracts selected for ASCO 2024 Annual Meeting

Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate’s second generation ANKET ® , for the treatment of relapsed/refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial Monalizumab SCLC Phase 2 MOZART trial poster Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced today that five abstracts with Innate’s drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois. ASCO abstract details: Lacutamab Abstract: 7082 Abstract Title: Lacutamab in patients with relapsed and/or refractory mycosis fungoides: results from the TELLOMAK Phase 2 trial First Author: Pierluigi Porcu Session Type: Poster Session Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Session Date and Time: Monday June 3, 2024 – 9:00 AM – 12:00 PM IPH6501 Abstract: TPS7095 Abstract Title: A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients With Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma First Author: Lorenzo Falchi Session Type: Poster Session Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Session Date and Time: Monday June 3, 2024 – 9:00 AM – 12:00 PM Abstract: 7030 Abstract Title: Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK Cell Engager directed against CD20 for R/R B-NHL, in comparison to a CD20-targeting T Cell Engager First Author: Olivier Demaria Session Type: Poster Session Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Session Date and Time: Monday June 3, 2024 – 9:00 AM – 12:00 PM Monalizumab (partnered with AstraZeneca) Abstract: 8046 Abstract Title: Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC) First Author: Charu Aggarwal Session Type: Poster Session Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Session Date and Time: Monday June 3, 2024 – 1:30 PM – 4:30 PM Abstract: TPS8129 Abstract Title: A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study. First Author: Hirva Mamdani Session Type: Poster Session Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Session Date and Time: Monday June 3, 2024 – 1:30 PM – 4:30 PM Subscribe to our newsletter Contact us 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30

The release as fetched from its publisher. innate-pharma.com ↗